A Selective and Potent CXCR3 Antagonist SCH 546738 Attenuates the Development of Autoimmune Diseases and Delays Graft Rejection

BMC Immunology - United Kingdom
doi 10.1186/1471-2172-13-2
Full Text
Abstract

Available in full text

Categories
Immunology
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Dihydroartemisinin Attenuates Autoimmune Thyroiditis by Inhibiting the CXCR3/PI3K/AKT/NF-κB Signaling Pathway

Oncotarget
Oncology
2017English

FPL 66096: A Novel, Highly Potent and Selective Antagonist at Human Platelet P2t-Purinoceptors

British Journal of Pharmacology
Pharmacology
1994English

The Experimental Treatment of Corneal Graft Rejection With the Interleukin-1 Receptor Antagonist (IL-1ra) Gene

PLoS ONE
Multidisciplinary
2013English

Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8

English

Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8

English

Z944, a Novel Selective T-Type Calcium Channel Antagonist Delays the Progression of Seizures in the Amygdala Kindling Model

PLoS ONE
Multidisciplinary
2015English

Development of Highly Potent and Selective Diaminothiazole Inhibitors of Cyclin-Dependent Kinases

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2013English

Vitiligo and Autoimmune Diseases

Przeglad Dermatologiczny
Dermatology
2016English

Antiemetic Effect of a Potent and Selective Neurokinin-1 Receptor Antagonist, FK886, on Cisplatin-Induced Acute and Delayed Emesis in Ferrets

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy